Intriguingly, a recent study elucidates the attenuation effect of systemic NR1D1 agonist administration on hepatic steatosis and inflammation in non-alcoholic steatohepatitis (NASH) mice might be attributed to the enhancement of gut barrier42. The gene discussed is NR1D1; the disease is fatty liver disease.